<DOC>
	<DOCNO>NCT01659944</DOCNO>
	<brief_summary>The primary objective determine effect repeat oral dos eliglustat 150 mg twice daily ( BID ) pharmacokinetics ( PK ) orally administer metoprolol 50 mg healthy adult . The secondary objective ass safety tolerability single oral dose metoprolol 50 mg administer alone combination repeat oral dos eliglustat 150 mg BID healthy adult .</brief_summary>
	<brief_title>Study Evaluate Effect Eliglustat Pharmacokinetics , Safety Tolerability Metoprolol Healthy Adults</brief_title>
	<detailed_description />
	<mesh_term>Metoprolol</mesh_term>
	<mesh_term>Eliglustat</mesh_term>
	<criteria>1 . The subject willing able provide sign informed consent . 2 . The male female subject good general health 18 40 year age , inclusive . 3 . The subject body weight 50 100 kg ( 110 220 lb ) body mass index ( BMI ) ≤32 kg/m2 screening . 4 . The subject 's physical examination , laboratory , vital sign , electrocardiogram ( ECG ) test result within normal limit screen Day 1 , abnormal , consider clinically significant opinion Investigator . 5 . The subject nonsmoker least 6 month prior time provide informed consent , willing able abstain smoking ( use form nicotine ) completion safety followup visit . 6 . The subject use drug abuse least 6 month prior Day 1 willing able abstain use drug abuse completion safety followup visit . 7 . The subject willing able abstain alcohol 48 hour prior first dose study drug completion safety followup visit . 8 . The subject willing able abstain grapefruit , grapefruit juice grapefruitcontaining product 72 hour prior first dose study drug completion safety followup visit . 9 . The subject willing able maintain normalfiber diet ( i.e. , abstain excess fiberrich food ) 72 hour prior first dose study drug completion safety followup visit . 10 . Female subject childbearing potential must document negative pregnancy test screening , Day 1 prior dose Day 7 willing use medically accept form contraception ( define protocol ) screen 30 day last dose study drug . A woman childbearing potential define female amenorrheic least 2 year undergone hysterectomy surgical sterilization . 1 . The subject classify cytochrome P450 2D6 ( CYP2D6 ) poor metabolizer ( indeterminate metabolizer neither allele know active ) base result CYP2D6 genotyping perform screen . ( Note : Prior CYP2D6 genotyping result may use purpose determine study eligibility copy laboratory report available genotyping result interpret classification system use study reference laboratory . ) 2 . The subject digestive disorder , include malabsorption , gastroenteritis , pancreatitis , gastroesophageal reflux disease , inflammatory bowel disease ( include Crohn 's disease ) , digestive disorder , opinion Investigator , may affect oral bioavailability ( e.g. , clinically significant constipation , diverticulitis , irritable bowel syndrome ) . 3 . The subject gastrointestinal ( GI ) surgical procedure might affect drug transit time , ( e.g. , cholecystectomy , GI bypass surgery , partial total gastrectomy , small bowel resection ) . 4 . The subject following : Clinically significant coronary artery disease include history myocardial infarction ongoing sign symptom consistent cardiac ischemia heart failure ; clinically significant arrhythmias conduction defect 2nd 3rd degree atrioventricular ( AV ) block , PR interval ≥200 msec , complete bundle branch block , prolong QTc interval ( e.g. , repeated demonstration QTc interval ≥430 msec male subject ≥450 msec female subject ) , sustain ventricular tachycardia , heart rate &lt; 55 beats/min , systolic blood pressure &lt; 110 mmHg . 5 . The subject clinically significant organic disease , include cardiovascular , renal , hepatic , gastrointestinal , pulmonary , neurologic , endocrine , metabolic , psychiatric disease , medical condition , serious intercurrent illness , extenuate circumstance , opinion Investigator , preclude participation trial . 6 . The subject disease , clinical finding , contraindication would prohibit use metoprolol phase 1 study ( i.e. , risk disease exacerbation outweigh benefit ) . Examples clinical finding glucose intolerance , poor arterial peripheral circulation bronchospastic disease include asthma . 7 . The subject history fainting , postural lightheadedness , postural symptom . 8 . The subject receive prescription nonprescription medication ( exception nonprescriptionstrength ibuprofen acetaminophen , topical nonsteroidal preparation , topical hydrocortisone ( 1 % strength ) ) dietary herbal fiber supplement within 30 day 5 halflives ( whichever longer ) prior first dose study drug without approval Investigator Sponsor . 9 . The subject receive immunization within 30 day provide informed consent . 10 . The subject receive investigational product within 30 day prior first dose study drug plan receive investigational product time course study . 11 . The subject history drug allergy clinically significant opinion Investigator ( e.g. , significant rash hive ) . 12 . The subject screening laboratory test result upper limit normal follow liver function test : aspartate aminotransferase ( AST ) , alanine aminotransferase ( ALT ) , gamma glutamyltransferase ( GGT ) , total bilirubin . 13 . The subject test positive human immunodeficiency virus ( HIV ) antibody , hepatitis C antibody , hepatitis B surface antigen screen . 14 . The subject test positive urine drug abuse , urine alcohol , urine cotinine screening . 15 . The subject donate blood blood product within 30 day prior provide inform consent . 16 . The subject 's schedule travel plan prevent completion require visit . 17 . The subject schedule inpatient hospitalization , include elective surgery ( inpatient outpatient ) , study . 18 . The subject history cancer , exception basal cell carcinoma . 19 . The female subject childbearing potential pregnant lactating . 20 . The subject , opinion Investigator , unable adhere requirement study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Drug-drug interaction</keyword>
</DOC>